Drug Profile
Research programme: Tie-1 targeted antibodies - Takeda
Alternative Names: Angiogensis inhibitors - Takeda; DX-2240Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Dyax
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Jan 2016 Dyax has been acquired by and merged into Shire